x
0 Activities
0 Activities
No Saved Activities
Please wait
Home
Education
Format
Interactive Case
Podcast
Primers/Supplements
Webinar
Videos
View All Education
Search Education
Register
Contact Us
Login
Login
Remember Me
Log in
Create an account
Forgot your password?
Search
Format
Interactive Case
Podcast
Primers/Supplements
Webinar
Videos
View All Education
All France Foundation Content
Credit Type
Format
Credits
Specialty Area
Disease Area
Alpha-1 Antitrypsin Deficiency
Amyloidosis
Aplastic Anemia
Asthma
Atrial fibrillation (AFib)
Atopic Dermatitis
Biosimilars
Blood Cancers
Bronchiectasis
Chronic Obstructive Pulmonary Disease
COVID-19 (SARS-CoV-2)
Cystic Fibrosis
Diabetes
Deep Vein Thrombosis (DVT)
Duchenne Muscular Dystrophy (DMD)
Epilepsy
Encephalopathy
Hepatocellular Carcinoma (HCC)
Fabry Disease
Hemophilia
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Limb Girdle Muscle Weakness (LGMW)
Multiple Sclerosis
Lysosomal Storage Disorders
Muscular Dystrophy
Non-Small Cell Lung Cancer (NSCLC)
Myeloma
Myelofibrosis
Nontuberculous Mycobacteria
Obesity
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Postpartum Depression
Psoriasis
Pulmonary Hypertension
Renal Cell Carcinoma
Respiratory Syncytial Virus (RSV)
Rheumatoid Conditions
Skin Cancer
Schizophrenia
Spinal Muscular Atrophy
Start
«
1
2
3
4
5
6
7
Page 7 of 7
Results 451 - 492 of 492
15
30
60
75
150
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
Switching Between Biologics: Is a Biosimilar an Option?
When to Switch? Biologically Experienced Psoriasis Patients
Innovator or Biosimilar for a Patient with Psoriasis
Interchangeability and Pharmacy-Level Substitution
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
What is the Difference Between a Biosimilar and a Generic?
What is a Biologic?
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
Are You Ready to Use Biosimilars in Your Practice?
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
Pharmacovigilance and Biosimilars: Any Special Considerations?
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
Biosimilars: As Safe and Effective as the Reference Product?
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
Radiologic Features of IPF
Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs
Elizabeth: Loves the outdoors but bothered by persistent cough and GERD
Toni: Too tired to continue teaching and experiencing painful heartburn
A 30 y/o Female w/2-year History of Shoulder Weakness and Elevated AST and ALT
32 y/o Male w/Progressive Weakness, Dilated Cardiomyopathy & Respiratory...
A 60 y/o Male w/4-year History Of Shoulder Weakness
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
Individualizing Patient Education in Treatment Choice: Practical Strategies
Addressing Common Barriers to Adherence
Approach to Genetic Testing in Myopathies
Molecular Diagnosis of Limb-Girdle Muscle Weakness
Discovering New Drugs for IPF
Biomarkers for IPF
New Trends in IPF
New Trends in IPF
Treatment Dilemmas Case Study: Harrison
A New Era in IPF: Trials and Treatments
Highlights from ATS 2014: Discussions on Clinical Trial Data
Highlights from ATS 2014: Update on Predicting Clinical Progression
Highlights from ATS 2014: Top Line Clinical Trial Results - ASCEND, INPULSIS, and PANTHER
Exciting IPF Developments from 2015 ERS
Exciting Developments from 2015 CHEST
Start
«
1
2
3
4
5
6
7
Page 7 of 7
A ACCME Accredited provider.
The France Foundation ©
10 Vista Drive, Old Lyme, CT USA
Search
Home
Education
Register
Contact Us
Login
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our
Privacy Policy
.
I accept